- Home
- AACT vs EOLS Comparison
AACT vs EOLS Comparison
Compare AACT & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACT
- EOLS
- Stock Information
- Founded
- AACT 2021
- EOLS 2012
- Country
- AACT United States
- EOLS United States
- Employees
- AACT N/A
- EOLS N/A
- Industry
- AACT
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- AACT
- EOLS Health Care
- Exchange
- AACT Nasdaq
- EOLS Nasdaq
- Market Cap
- AACT 677.5M
- EOLS 702.2M
- IPO Year
- AACT 2023
- EOLS 2018
- Fundamental
- Price
- AACT $11.00
- EOLS $14.10
- Analyst Decision
- AACT
- EOLS Strong Buy
- Analyst Count
- AACT 0
- EOLS 6
- Target Price
- AACT N/A
- EOLS $22.60
- AVG Volume (30 Days)
- AACT 75.8K
- EOLS 695.8K
- Earning Date
- AACT 01-01-0001
- EOLS 03-06-2025
- Dividend Yield
- AACT N/A
- EOLS N/A
- EPS Growth
- AACT 48.19
- EOLS N/A
- EPS
- AACT 0.43
- EOLS N/A
- Revenue
- AACT N/A
- EOLS $248,326,000.00
- Revenue This Year
- AACT N/A
- EOLS $33.43
- Revenue Next Year
- AACT N/A
- EOLS $32.44
- P/E Ratio
- AACT $25.56
- EOLS N/A
- Revenue Growth
- AACT N/A
- EOLS 34.42
- 52 Week Low
- AACT $10.47
- EOLS $9.25
- 52 Week High
- AACT $11.02
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- AACT 65.98
- EOLS 68.82
- Support Level
- AACT $10.95
- EOLS $9.25
- Resistance Level
- AACT $11.00
- EOLS $14.49
- Average True Range (ATR)
- AACT 0.02
- EOLS 0.64
- MACD
- AACT 0.00
- EOLS 0.42
- Stochastic Oscillator
- AACT 71.43
- EOLS 87.02
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.